Drug intelligence / Profile preview

ANXA2 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intraperitoneal, Intravitreal, Parenteral
01

Overview

ANXA2 siRNA is a research-grade small interfering RNA (siRNA) designed to silence the expression of the ANXA2 gene, which encodes the Annexin A2 protein. Annexin A2 is a calcium-dependent phospholipid-binding protein involved in various cellular processes, including endocytosis, exocytosis, and cell-matrix interactions. In oncological research, ANXA2 is often overexpressed and associated with tumor progression, migration, and invasion. The siRNA works through the RNA interference (RNAi) pathway, where it is incorporated into the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage and degradation of ANXA2 mRNA, thereby preventing the translation of the Annexin A2 protein. It is primarily utilized as a laboratory tool for in vitro and in vivo preclinical studies across various cancers and fibrotic conditions.

Other names
Annexin A2 siRNAsiRNA targeting ANXA2
02

Targets

ANXA2 (Annexin A2)

Beyond the preview

Go deeper on ANXA2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANXA2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call